EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients

BACKGROUND: Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor (TKI) with robust activity in advanced EGFR-mutant non-small cell lung cancer (NSCLC), including those with T790M resistance mutation. However, a broad interpatient variability was observed. This study aimed to evalu...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Transl Lung Cancer Res
Glavni autori: Zheng, Qiufan, Huang, Yan, Zhao, Hongyun, Yang, Yunpeng, Hong, Shaodong, Hou, Xue, Zhao, Yuanyuan, Ma, Yuxiang, Zhou, Ting, Zhang, Yaxiong, Fang, Wenfeng, Zhang, Li
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2020
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7354104/
https://ncbi.nlm.nih.gov/pubmed/32676311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2020.03.35
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items